Program
Clopidogrel
Also written as “clopidogrel”, “clopidogrel (SR25990C)” and “Clopidogrel (SR25990)”.
Its studies are mostly in Coronary Artery Disease · Cardiovascular Diseases · Acute Coronary Syndrome · Heart Defects, Congenital · Diabetes Mellitus, Type 2, led by 17 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 250 open or running | phase 4since Feb 23, 2006 | Dec 20, 2002 | none ahead |
| Dr. Reddy's Laboratories | 40 open or running | phase 1since Jan 6, 2012 | Jan 6, 2012 | none ahead |
| AstraZeneca | 30 open or running | phase 1since Jun 4, 2010 | Jun 4, 2010 | none ahead |
| Bristol-Myers Squibb | 30 open or running | phase 1since Jul 8, 2009 | Jul 8, 2009 | none ahead |
| Eli Lilly | 30 open or running | phase 2since Jul 26, 2006 | Jul 26, 2006 | none ahead |
| Viatris | 30 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| Johnson & Johnson | 20 open or running | phase 2since Nov 13, 2014 | Nov 13, 2014 | none ahead |
| les-laboratoires-des-me-dicaments-ste-riles | 20 open or running | phase 4since Aug 25, 2011 | Aug 25, 2011 | none ahead |
| Merck | 20 open or running | phase 1since Nov 10, 2009 | Nov 10, 2009 | none ahead |
| accumetrics-inc | 10 open or running | no phasesince Mar 24, 2008 | Mar 24, 2008 | none ahead |
| Boston Scientific | 10 open or running | phase 4since May 1, 2012 | May 1, 2012 | none ahead |
| Cordis | 10 open or running | phase 4since Aug 6, 2009 | Aug 6, 2009 | none ahead |
| Hanmi Pharmaceutical | 10 open or running | phase 4since Apr 5, 2013 | Apr 5, 2013 | none ahead |
| laboratoires-teriak | 10 open or running | phase 4since Oct 14, 2017 | Oct 14, 2017 | none ahead |
| Novo Nordisk | 10 open or running | phase 1since May 16, 2012 | May 16, 2012 | none ahead |
| Otsuka | 10 open or running | phase 1since Sep 15, 2015 | Sep 15, 2015 | none ahead |
| Pharmtechnology | 10 open or running | phase 1since Jun 28, 2023 | Jun 28, 2023 | none ahead |
Also a collaborator on its studies: Bayer and Daiichi Sankyo.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 40 studies since Dec 20, 2002.
- Jan 9, 2012Phase 4 study in Cardiovascular Diseasesles-laboratoires-des-me-dicaments-ste-riles · NCT01509365 · 116 enrolled · Tunisia
- May 1, 2012Boston Scientific's first study: phase 4 study in Coronary Artery DiseaseNew to Boston ScientificBoston Scientific · NCT01589978 · 2,681 enrolled · United States
- May 16, 2012Novo Nordisk's first study: phase 1 study in HaemostasisNew to Novo NordiskNovo Nordisk · NCT01603342 · 18 enrolled · United States
- Jun 14, 20122 phase 1 studiesDr. Reddy's Laboratories · NCT01621763, NCT01621750
- Apr 5, 2013Hanmi Pharmaceutical's first study: phase 4 study in Coronary Artery DiseaseNew to Hanmi PharmaceuticalHanmi Pharmaceutical · NCT01830491 · 162 enrolled
- Jul 4, 2014Phase 1 study in Bioequivalence, AUC, Cmax, PharmacokineticsAstraZeneca · NCT02185534 · 144 enrolled · Germany
- Nov 13, 2014Johnson & Johnson's first study: phase 2 study in Acute Coronary SyndromeNew to Johnson & JohnsonJohnson & Johnson · NCT02293395 · 3,037 enrolled · United States, Argentina, Australia and more
- Apr 2, 2015Phase 1 study in ThrombosisBristol-Myers Squibb · NCT02439190 · 42 enrolled · United Kingdom
- Sep 15, 2015Otsuka's first study: phase 1 study in HealthyNew to OtsukaOtsuka · NCT02554721 · 77 enrolled · Germany
- Oct 14, 2017laboratoires-teriak's first study: phase 4 study in Diabetes Mellitus, Type 2New to laboratoires-teriaklaboratoires-teriak · NCT03329261 · 167 enrolled · Tunisia
- Jan 30, 2018Phase 1 study in HealthyViatris · NCT03430661 · 77 enrolled · United States
- Apr 6, 2018Phase 1 study in Healthy SubjectsJohnson & Johnson · NCT03496506 · 22 enrolled · Belgium
- Oct 4, 2018Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT03698513 · 113 enrolled · United States
- Jun 28, 2023Pharmtechnology's first study: phase 1 study in BioequivalenceNew to PharmtechnologyPharmtechnology · NCT05934799 · 60 enrolled · Russian Federation
TargetBeta
“Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 antagonist”ChEMBL 37, by rule
Other programs on P2RY12
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Ticagrelorrule | AstraZeneca | phase 4 | 47 |
| selatogrelrule | Viatris | phase 3 | 11 |
Studies
All 55 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05934799Bioequivalence · Russian Federation | 1 | Completed | Pharmtechnology | Jul 23, 2023 | 60 |
| NCT03698513Healthy Volunteers · United States | 1 | Completed | Bristol-Myers Squibb | Feb 19, 2019 | 113 |
| NCT03496506Healthy Subjects · Belgium | 1 | Completed | Johnson & Johnson | May 10, 2018 | 22 |
| NCT03430661Healthy · United States | 1 | Completed | Viatris | May 20, 2019 | 77 |
| NCT03329261Diabetes Mellitus, Type 2 · Tunisia | 4 | Completed | laboratoires-teriak | Mar 24, 2019 | 167 |
| NCT02554721Healthy · Germany | 1 | Completed | Otsuka | Mar 30, 2018 | 77 |
| NCT02439190Thrombosis · United Kingdom | 1 | Completed | Bristol-Myers Squibb | Mar 2016 | 42 |
| NCT02293395Acute Coronary Syndrome · United States, Argentina, Australia and more | 2 | Completed | Johnson & Johnson | Oct 14, 2016 | 3,037 |
| NCT02185534Bioequivalence, AUC, Cmax, Pharmacokinetics · Germany | 1 | Completed | AstraZeneca | Oct 2014 | 144 |
| NCT01830491Coronary Artery Disease | 4 | Completed | Hanmi Pharmaceutical | Aug 2009 | 162 |
| NCT01621763Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Sep 2008 | 68 |
| NCT01621750Fasting · India | 1 | Completed | Dr. Reddy's Laboratories | Sep 2008 | 68 |
| NCT01603342Haemostasis · United States | 1 | Completed | Novo Nordisk | Jan 2008 | 18 |
| NCT01589978Coronary Artery Disease · United States | 4 | Completed | Boston Scientific | Aug 2014 | 2,681 |
| NCT01512485Healthy · Canada | 1 | Completed | Dr. Reddy's Laboratories | Oct 2006 | 51 |
| NCT01509365Cardiovascular Diseases · Tunisia | 4 | Completed | les-laboratoires-des-me-dicaments-ste-riles | Feb 2015 | 116 |
| NCT01506713Fasting · Canada | 1 | Completed | Dr. Reddy's Laboratories | Sep 2006 | 53 |
| NCT01431495Coronary Disease · Tunisia | 4 | Completed | les-laboratoires-des-me-dicaments-ste-riles | Jun 2011 | 219 |
| NCT01263093Depressive Disorder, Major · United States | 1 | Completed | Eli Lilly | Mar 2011 | 47 |
| NCT01210339Cardiovascular Diseases · Sweden | 1 | Completed | AstraZeneca | Aug 2011 | 58 |
| NCT01147588Healthy · United States | 1 | Completed | AstraZeneca | May 2011 | 149 |
| NCT01129427Healthy · United States | 1 | Completed | Sanofi | Nov 2009 | 66 |
| NCT01129414Healthy · United States | 1 | Completed | Sanofi | Aug 2009 | 72 |
| NCT01129388Healthy · United States | 1 | Completed | Sanofi | May 2009 | 72 |
| NCT01129375Healthy · United States | 1 | Completed | Sanofi | May 2009 | 72 |
| NCT01129271Healthy · United States, France | 1 | Completed | Sanofi | Jun 2009 | 72 |
| NCT01129063Healthy · France | 1 | Completed | Sanofi | May 2009 | 32 |
| NCT01123824Healthy · Germany | 1 | Completed | Sanofi | Aug 2009 | 40 |
| NCT01115738Acute Coronary Syndrome · India | 2 | Completed | Eli Lilly | Nov 2011 | 282 |
| NCT01108588Healthy Volunteers | 1 | Completed | Merck | Aug 2010 | 15 |
| NCT01012219Hyperlipoproteinemia Type II | 1 | Completed | Merck | Mar 2010 | 36 |
| NCT00954707Coronary Artery Disease · United States | 4 | UNKNOWN | Cordis | Jan 2012 | 2,509 |
| NCT00935506Cardiovascular Diseases · United States | 1 | Completed | Bristol-Myers Squibb | Oct 2009 | 15 |
| NCT00862420Peripheral Arterial Disease · Japan | 3 | Completed | Sanofi | May 2011 | 431 |
| NCT00833703Heart Defects, Congenital · United States, Brazil, France and more | 3 | Completed | Sanofi | Jul 2010 | 49 |
| NCT00821834Angina, Stable · Japan | 3 | Completed | Sanofi | Aug 2010 | 1,003 |
| NCT00814268Stroke · Korea, Republic of | 4 | Completed | Sanofi | May 2012 | 358 |
| NCT00716924Thrombosis · Mexico | 3 | Completed | Sanofi | Feb 2006 | 155 |
| NCT00714961Acute Coronary Syndrome · United States, Argentina, Australia and more | 3 | Completed | Sanofi | Jan 2005 | 3,491 |
| NCT00650169Healthy · United States | 1 | Completed | Viatris | Jan 2005 | 47 |
| NCT00648947Healthy · United States | 1 | Completed | Viatris | Dec 2004 | 46 |
| NCT00648453Peripheral Arterial Disease · Hungary | 4 | Completed | Sanofi | 39 | |
| NCT00645918Coronary Artery Disease · United States, Canada | – | Completed | accumetrics-inc | Oct 2010 | 2,800 |
| NCT00396877Heart Defects, Congenital · United States, Argentina, Belgium and more | 3 | Completed | Sanofi | Feb 2010 | 906 |
| NCT00386191Cerebral Infarction · Japan | 4 | Completed | Sanofi | Dec 2008 | 1,110 |
| NCT00360386Ischemia | 2 | Completed | Sanofi | Feb 2005 | 110 |
| NCT00357968Coronary Artery Disease · United States, France, Germany and more | 2 | Completed | Eli Lilly | Jun 2007 | 201 |
| NCT00335452Angina, Unstable · United States, Argentina, Australia and more | 3 | Completed | Sanofi | Sep 2009 | 25,086 |
| NCT00325390Platelet Aggregation Inhibitors · Japan | 3 | Completed | Sanofi | 800 | |
| NCT00296803Metabolic Syndrome · United States | 4 | Completed | Sanofi | 216 | |
| NCT00249873Atrial Fibrillation · United States, Argentina, Australia and more | 3 | Completed | Sanofi | Mar 2009 | 7,554 |
| NCT00243178Atrial Fibrillation · United States, Australia, Austria and more | 3 | Terminated | Sanofi | Sep 2005 | 6,706 |
| NCT00174759Arterial Occlusive Diseases · Australia, Austria, Belgium and more | 3 | Completed | Sanofi | 1,460 | |
| NCT00115375Heart Defects, Congenital · United States, Belgium, Canada and more | 2 | Completed | Sanofi | 92 | |
| NCT00050817Arteriosclerosis · United States, Argentina, Australia and more | 3 | Completed | Sanofi | 15,603 |
How it is read
Names in the registry
- “Clopidogrel”, 41 entries
- “clopidogrel”, 11 entries
- “clopidogrel (SR25990C)”, 4 entries
- “Clopidogrel (SR25990)”, 3 entries
- “clopidogrel (SR25990)”, 3 entries
Conditions, from the studies’ own filings
- Coronary Artery Disease, 5 studies
- Cardiovascular Diseases, 4 studies
- Acute Coronary Syndrome, 3 studies
- Heart Defects, Congenital, 3 studies
- Diabetes Mellitus, Type 2, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.